Quarterly report pursuant to Section 13 or 15(d)

Acquisition - Additional Information (Detail)

v3.20.2
Acquisition - Additional Information (Detail) - USD ($)
Jun. 11, 2018
Aug. 31, 2020
Nov. 30, 2019
Business Acquisition [Line Items]      
Common stock par value   $ 0.01 $ 0.01
Goodwill   $ 1,941,411 $ 1,941,411
Blood Bank Inc and Tianhe Stem Cell Biotechnologies Inc [Member]      
Business Acquisition [Line Items]      
Aggregate consideration payable at closing under the Purchase Agreement $ 14,000,000    
Payment under asset purchase agreement $ 10,500,000    
Shares issued under asset purchase agreement 465,426    
Common stock par value $ 0.01    
Sale of stock price per share $ 7.52    
Percentage of earn out to be paid from gross revenues 75.00%    
Common stock deliver $ 200,000    
Common stock value 5,000,000    
Amount of earn out to be paid from sale of public cord blood inventory $ 500,000